Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Cash from Investing Activities: 2012-2024

Historic Cash from Investing Activities for Akebia Therapeutics (AKBA) over the last 12 years, with Dec 2024 value amounting to -$33,000.

  • Akebia Therapeutics' Cash from Investing Activities fell 3750.00% to -$77,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$51,000, marking a year-over-year decrease of 100.26%. This contributed to the annual value of -$33,000 for FY2024, which is N/A change from last year.
  • As of FY2024, Akebia Therapeutics' Cash from Investing Activities stood at -$33,000, which was up 71.05% from -$114,000 recorded in FY2022.
  • Akebia Therapeutics' 5-year Cash from Investing Activities high stood at $39.9 million for FY2021, and its period low was -$40.0 million during FY2020.
  • In the last 2 years, Akebia Therapeutics' Cash from Investing Activities had a median value of -$73,500 in 2022 and averaged -$73,500.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 118.94% in 2020, then surged by 199.84% in 2021.
  • Akebia Therapeutics' Cash from Investing Activities (MRY) stood at -$40.0 million in 2020, then skyrocketed by 199.84% to $39.9 million in 2021, then tumbled by 100.29% to -$114,000 in 2022, then surged by 71.05% to -$33,000 in 2024.
  • Its Cash from Investing Activities was -$33,000 in FY2024, compared to -$114,000 in FY2022 and $39.9 million in FY2021.